Use of monoclonal antibody 1H1, anticortactin, to distinguish normal and neoplastic smooth muscle cells: comparison with anti-alpha-smooth muscle actin and antimuscle-specific actin

Application of immunohistochemistry to soft tissue neoplasms

CONTEXT

Soft tissue tumors are composed of numerous and complex diagnostic entities. Because of this complexity and the recognition of an intermediate malignancy category including some tumors with a deceptively bland histologic appearance, soft tissue tumors may represent a major diagnostic challenge to the general practicing pathologist.

OBJECTIVE

To correctly diagnose soft tissue tumors with the ancillary use of immunohistochemistry.

DATA SOURCES

Review of the current literature with emphasis on those tumors for which immunohistochemistry has proven to be particularly useful.

CONCLUSIONS

Immunohistochemistry plays an important role in the diagnosis of soft tissue tumors. One of its major utilities is to correctly identify a tumor as being of mesenchymal or nonmesenchymal origin. Once mesenchymal origin has been established, histologic subtyping according to specific cell lineage may be achieved with the use of lineage-specific markers. Tumors of uncertain cell lineage and tumors with primitive small round cell morphology are often characterized by a unique immunohistochemical phenotype. In this group of tumors, immunohistochemistry is most widely applied and is of greatest value. Despite the rapid development of molecular genetic techniques, immunohistochemistry still remains the most important diagnostic tool in the diagnosis of soft tissue tumors aside from recognition of morphologic features and clinical correlation.

Clear cell atypical fibroxanthoma:a clinicopathologic study

INTRODUCTION

The atypical fibroxanthoma (AFX) is considered by most authorities to represent a superficial or minimally invasive variant of malignant fibrous histiocytoma that most often presents as a solitary nodule on the sun-exposed skin of the elderly. Among the rarest variants is the clear cell AFX, a lesion which raises consideration to a differential diagnosis encompassing a variety of neoplastic and non-neoplastic clear cell proliferations.

METHODS

We describe three cases of a distinctive cutaneous neoplasm arising in the sun-exposed skin of elderly patients. In all cases, formalin-fixed, paraffin-embedded tissue was available for analysis. The histology in concert with the immunophenotype was held to be diagnostic of the clear cell variant of AFX.

RESULTS

All tumors comprised sheets of large cells with foamy cytoplasms and hyperchromatic, polyploid nuclei manifesting frequent and atypical mitoses. The critical cells in our cases expressed CD68 but none of CD3, CD20, CD34, S-100 protein, muscle-specific actin, factor XIIIa, Melan-A, carcinoembryonic antigen, or cytokeratin.

CONCLUSION

Although typical examples of AFX provoke diagnostic consideration of spindle cell cancers of the skin (most often spindle cell melanoma, spindle cell squamous cell carcinoma, and leiomyosarcoma), the clear cell variant raises other differential diagnostic considerations instead. These include balloon cell melanoma, sebaceous carcinoma, pleomorphic liposarcoma, chordoma, parachordoma, tricholemmal carcinoma and clear cell squamous cell carcinoma. A diagnosis of AFX is one of exclusion; one must employ immunohistochemical markers to rule out the aforementioned differential diagnostic considerations. By reporting the fifth, sixth and seventh cases of clear cell AFX, we hope to alert dermatopathologists to this distinctive and unusual neoplasm, recognition of which is essential to avoid under- or over-diagnosis and inappropriate therapy.

Cortactin localization in actin-containing adult and fetal tissues

Cortactin is a tyrosine kinase substrate that binds to filamentous actin. It represents a highly conserved family of perimembrane signaling proteins. The human homologue of cortactin is encoded by gene EMS1, which is amplified in some human breast, head, and neck carcinomas. This study shows that cortactin is preferentially localized to the apical surfaces of the polarized epithelium, specifically, to the terminal web of small bowel epithelium and to apical surfaces of the proximal renal tubules, thyroid follicles, and bronchiolar epithelium. Cortactin is also seen in cell and tissue types with actin-based contractile capacities, including smooth and striated muscle and myoepithelium.

Expression of myogenic marker proteins in human leiomyosarcoma

A series of formalin-fixed, paraffin-embedded leiomyosarcomas (n = 11) was studied immunohistochemically for their expression of various myogenic marker proteins. According to their predominant histological appearance, the tumors were classified as well (n = 4), moderately (n = 5), or poorly (n = 2) differentiated. Using monoclonal anti-muscle specific actin antibodies from clone HHF35 all examined tumors were positively stained. Desmin was not always found in leiomyosarcomas, since positive staining could be demonstrated only in eight cases. As revealed by staining with anti-vinculin antibodies from clone hVIN-1 using the APAAP technique, all leiomyosarcomas with the exception of one expressed vinculin. Typically, the vinculin immunoreactivity was detected diffusely throughout the majority of neoplastic cells as well as in vascular smooth muscle cells of blood vessels. Nine leiomyosarcomas displayed a positive staining for calponin, an actin-binding protein expressed in smooth muscle cells and their precursors. The distribution of calponin resembled that of vinculin in decorating myofibrils of nearly all tumor cells. Actinin immunoreactivity was present in tumor cells of all cases, but was expressed also in nontumor cells such as epithelia. These results suggest that the monoclonal antibodies against vinculin and calponin may serve as additional diagnostic markers for myogenic differentiation in leiomyosarcomas and related tumors.